Stockscreener 앱 받기
7.565
0.87%
0.075
전일 마감가:
$7.49
열려 있는:
$7.5
하루 거래량:
32,235
Relative Volume:
0.35
시가총액:
$54.72M
수익:
-
순이익/손실:
$-101.87M
주가수익비율:
-6.5783
EPS:
-1.15
순현금흐름:
$-83.46M
1주 성능:
+0.47%
1개월 성능:
-4.64%
6개월 성능:
-2.63%
1년 성능:
-14.15%
1일 변동 폭
$7.47
$7.63
1주일 범위
$7.21
$7.65
52주 변동 폭
$5.202
$11.35
Kezar Life Sciences Inc Stock (KZR) Company Profile
명칭
Kezar Life Sciences Inc
전화
650-822-5600
주소
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
KZR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| KZR | 7.57 | 54.72M | 0 | -101.87M | -83.46M | -1.15 |
| VRTX | 449.50 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.01 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.69 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.08 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Wells Fargo | Outperform |
| 2018-07-16 | 개시 | William Blair | Outperform |
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World
Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World
Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - MarketBeat
Kezar struck again with second FDA hold - Clinical Trials Arena
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Kezar Life Sciences Reports $20.3M Q3 Loss, Halts Key Lupus Trial Amid Safety Concerns | KZR Stock News - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar stock falls 11% after board rejects Concentra offer (update) - MSN
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar to focus on AIH drug after halting lupus trial - Investing.com
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan
Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Increases By 13.6% - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short Interest - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given "Neutral" Rating at HC Wainwright - MarketBeat
H.C. Wainwright maintains Neutral rating on Kezar shares amid acquisition bid - Investing.com UK
Concentra Biosciences proposes to buy Kezar Life Sciences - Investing.com India
Concentra Biosciences proposes to buy Kezar Life Sciences By Investing.com - Investing.com Australia
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - BioSpace
Concentra boss eyes up struggling Kezar - The Pharma Letter
Analyzing Kezar Life Sciences Inc (KZR) After Recent Trading Activity - Knox Daily
Mackenzie Financial Corp Invests $35,000 in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $80.3 million. - Marketscreener.com
With Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisition - Fierce Biotech
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc - Yahoo Finance
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sci - GuruFocus.com
After-hours movers: Astera Labs, Saratoga Investment, Kezar Life Sciences, and more By Investing.com - Investing.com Canada
A new trading data show Kezar Life Sciences Inc (KZR) is showing positive returns. - SETE News
Post-Trade Analysis: Kezar Life Sciences Inc (KZR) Slides -2.95, Closing at 0.77 - The Dwinnex
Kezar Life Sciences Inc (KZR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):